AroCell announced today that the patent no. 15/357 762 and titled” Method for use of antibody-based test for the prediction of cancer relapse - all immunoassays against TK1 “ is granted by United States Patent and Trademark Office.
The patent describes the use of TK1 antibody-based test for prediction of early cancer progression and the likelihood of tumor recurrence. It is estimated based on the binding response of TK1 in clinical samples to antibodies.
“We are delighted that the U.S. Patent and Trademark Office has granted this patent. This reinforce our patent position in the U.S. and increases AroCell’s attractiveness as a business partner. We will continue to develop our portfolio of proprietary assets to further expand its business opportunities.” Says Michael Brobjer, CEO AroCell.